AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi
Go back to AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi| AbbVie (NYSE: ABBV) | Delayed: 248.78 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $248.78 | 52 Week High | $68.12 | |||
| Open | $248.78 | 52 Week Low | $50.71 | |||
| Day High | $248.78 | P/E | 53.97 | |||
| Day Low | $248.78 | EPS | $4.61 | |||
| Volume | 269 | |||||
